Forecast

The analysts' average price target is €45.20 (+21.77%). The median is €46.19 (+24.43%).

Buy	3
Hold	0
Sell	0

News Go to news feed

LB Pharmaceuticals appoints Dr. Susan G. Kozauer as chief medical officer

LB Pharmaceuticals has appointed Dr. Susan G. Kozauer as chief medical officer. Kozauer brings more than 20 years of experience in developing neuropsychiatric drugs, most recently serving as senior vice president and head of clinical development at Centessa Pharmaceuticals. The appointment comes ahead of the expected topline results from the Phase 3 NOVA‑2 trial of LB‑102 for schizophrenia, anticipated in the first half of 2027. Kozauer holds a degree from Cornell, an MD from George Washington University, and completed a psychiatry residency at Georgetown University Hospital. » More on de.investing.com

Financials

In the last quarter, LB Pharmaceuticals had revenue of €0 and net profit of -€45.22m

(EUR)	June 2026	YoY
Revenue	0	-
Gross profit	-84.99k	-
Net profit	-45.22m	947.33%
EBITDA	-47.16m	965.48%

Fundamentals

Metric	Value
Market capitalization	€1.06bn
Number of shares	28.68m
52-week high/low	€43.71 - €11.64
Dividends	No
Beta	0.42
P/E ratio	-14.33
PEG ratio	-0.08
P/B ratio	3.86
P/S ratio	0.00

Company profile

Biopharmazeutisches Unternehmen im klinischen Stadium, das neuartige Therapien für neuropsychiatrische Erkrankungen (z. B. Schizophrenie, bipolare Depression) entwickelt. Hauptkandidat ist LB-102, ein methyliertes Derivat von Amisulprid.